KCT0008599招募中Unknown
Comparative study of efficacy of rabeprazole and lansoprazole for endoscopic submucosal dissection-induced ulcer
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •(1) A person who is 19 years of age or older as the date of obtaining written consent
- •(2) Among patients diagnosed with early gastric cancer and gastric adenoma and to undergo endoscopic submucosal dissection, endoscopic submucosal dissection was performed for differentiated early cancer of less than 2 cm without ulcer localized in the mucous membrane, adenoma and dysplasia greater than 1.5 cm, It targets adenomas accompanied by fibrosis.
- •(3) A person who voluntarily decided to participate and gave written consent to the consent form for clinical trial subjects
排除标准
- •(1) Those who cannot complete the questionnaire by themselves
- •(2) Those with a history of hypersensitivity to PPI-type ingredients or benzimidazoles
- •(3) Those who are taking drugs such as warfarin, phenytoin, theophylline, diazepam, etc.
- •(4) Patients who have taken PPI, histamine 2 receptor antagonist (H2RA), or potassium-competitive acid blockers (P-CAB) drugs within 4 weeks of performing endoscopic mucosal resection ruler
- •(5) Those with clinically significant disorders in the liver, kidneys, cardiovascular system, respiratory system, endocrine system, and central nervous system
- •(6) Those who showed the following abnormal values in blood chemistry tests within 4 weeks of endoscopic mucosal resection
- •- BUN, creatinine > 2 times the organ upper limit of normal
- •- AST, ALT, ALP, total bilirubin > 2 times the upper limit of normal
- •(7) Pregnant and lactating women or those who intend to become pregnant
- •(8) Patients with a history of alcohol abuse. Those who are judged difficult to participate in research due to bipolar disorder, anxiety disorder, panic disorder, somatoform disorder, personality disorder, or other psychiatric disorders
- •(9) Those who cannot undergo upper gastrointestinal endoscopy (esophageal disease, gastrointestinal bleeding, etc.)
- •(10) Those for whom endoscopic submucosal resection is contraindicated (thrombocytopenia, coagulopathy, etc.)
- •(11) Those who have undergone surgery that may affect gastric acid secretion
- •(12) Those who have taken contraindications to use in combination with the approval of investigational drugs (atazanavir, nelfinavir, or rilpivirine-containing agents, etc.), antiplatelet agents, and anticoagulants within 1 week of endoscopic mucosal resection
- •(13) A person who has not obtained the informed consent of the subject and guardian
- •(14) In addition to the above, those who have clinically significant findings that are considered inappropriate for this test based on medical judgment by the tester
研究者
相似试验
已完成
4 期
A clinical trial to study the effects of two drugs, Ilaprazole and Rabeprazole in patients with uninvestigated dyspepsiaCTRI/2014/02/004413Institute of Postgraduate Medical Education Research122
尚未招募
Unknown
Clinical Efficacy of rabeprazole in patients treated with dual antiplatelet agents including potent P2Y12 inhibitors after percutaneous coronary intervention for acute coronary syndromeKCT0008344Yonsei University Yongin Severance Hospital50
已完成
不适用
Comparison of effects of rabeprazole sodium SAWAI 10 mg and Pariet 10mg tablets on acid secretion using 24-hour gastric pH monitoringJPRN-UMIN000003837Tokyo-Eki Center-building Clinic8
已完成
4 期
Comparing omeprazole and ranitidine in treatment of gasteroesophageal reflux disease in pretem neonatesGastroesophageal reflux in premature neonate.Other specified perinatal digestive system disordersIRCT2016030226876N1Investigator60
进行中（未招募）
1 期
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With RabeprazoleEUCTR2016-001879-73-Outside-EU/EEAEisai Medical Research Inc.111